Tissue-specific antigens in GVL

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Immunity directed against leukemia in the setting of allogeneic bone marrow transplant, which has been termed GVL, is often accompanied by unwanted GVHD. Much clinical and laboratory evidence now exists showing that both reactions are mediated by T cells contained in the graft [1-3] as detailed in other chapters. Methods to reduce GVHD have included infusions of marrow or peripheral blood following depletion of T cells by either nonselective (anti-CD3) or selective (anti-CD8, -T10B9, or -Campath) means. Although GVHD is sometimes diminished by these maneuvers, none result in the infusion of only leukemia-specific T cells. If marrow or peripheral blood grafts could be enriched for such leukemia-specific T cells, GVHD might be significantly reduced or even eliminated.

Original languageEnglish (US)
Title of host publicationAllogeneic Immunotherapy for Malignant Diseases
PublisherCRC Press
Pages135-153
Number of pages19
ISBN (Electronic)9780203909508
ISBN (Print)9780824767815
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Tissue-specific antigens in GVL'. Together they form a unique fingerprint.

  • Cite this

    Molldrem, J. J. (2000). Tissue-specific antigens in GVL. In Allogeneic Immunotherapy for Malignant Diseases (pp. 135-153). CRC Press.